Schizophrenia Relapse Prevention

Neurology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Seroquel XR in Schizophrenia Relapse PreventionN/A1 trial
Active Trials
NCT00990626Completed1,600Est. Jul 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaSeroquel XR in Schizophrenia Relapse Prevention

Clinical Trials (1)

Total enrollment: 1,600 patients across 1 trials

NCT00990626AstraZenecaSeroquel XR in Schizophrenia Relapse Prevention

Seroquel XR in Schizophrenia Relapse Prevention

Start: Oct 2009Est. completion: Jul 20101,600 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
11h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
11h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
11h ago

Director of Finance

CoMind
London, UK
11h ago

Electronics Engineering Manager

CoMind
London, UK
11h ago

Director of Information Technology

Zavation Medical Products
11h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)